Skip to main content

Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth

Merck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.